Harrow, Inc. Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease)
Harrow, Inc. (HROW) reported Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease) of -$195.00 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-11.
Financial Statements › Notes › Accounts, Notes, Loans and Financing Receivable, Gross, Allowance, and Net
us-gaap:AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease · last filed 2026-05-11
- Harrow, Inc. accounts receivable, allowance for credit loss, period increase (decrease) for the quarter ending 2026-03-31 was -$195.00K, a 271.05% decline year-over-year.
- Harrow, Inc. accounts receivable, allowance for credit loss, period increase (decrease) for the quarter ending 2025-12-31 was $7.00K, a 95.00% decline year-over-year.
- Harrow, Inc. accounts receivable, allowance for credit loss, period increase (decrease) for the quarter ending 2025-09-30 was $208.00K, a 173.68% increase year-over-year.
- Harrow, Inc. accounts receivable, allowance for credit loss, period increase (decrease) for the quarter ending 2025-06-30 was $226.00K.
- Harrow, Inc. accounts receivable, allowance for credit loss, period increase (decrease) for fiscal 2025 was $555.00K, a 362.50% increase from fiscal 2024.
- Harrow, Inc. accounts receivable, allowance for credit loss, period increase (decrease) for fiscal 2024 was $120.00K, a 63.86% decline from fiscal 2023.
- Harrow, Inc. accounts receivable, allowance for credit loss, period increase (decrease) for fiscal 2023 was $332.00K.
| Period end | Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease) 3 month | Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease) 6 month | Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease) 9 month | Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2026-03-31 | -$195.00K 10-Q · filed 2026-05-11 | -$188.00K derived: sum of 2 quarters · filed 2026-05-11 | $20.00K derived: sum of 3 quarters · filed 2026-05-11 | $246.00K derived: sum of 4 quarters · filed 2026-05-11 |
| 2025-12-31 | $7.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $215.00K derived: sum of 2 quarters · filed 2026-03-02 | $441.00K derived: sum of 3 quarters · filed 2026-03-02 | $555.00K 10-K · filed 2026-03-02 |
| 2025-09-30 | $208.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $434.00K derived: sum of 2 quarters · filed 2025-11-10 | $548.00K 10-Q · filed 2025-11-10 | $688.00K derived: sum of 4 quarters · filed 2026-03-02 |
| 2025-06-30 | $226.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $340.00K 10-Q · filed 2025-08-11 | $480.00K derived: sum of 3 quarters · filed 2026-03-02 | $556.00K derived: sum of 4 quarters · filed 2026-03-02 |
| 2025-03-31 | $114.00K 10-Q · filed 2025-05-08 | $254.00K derived: sum of 2 quarters · filed 2026-03-02 | $330.00K derived: sum of 3 quarters · filed 2026-03-02 | |
| 2024-12-31 | $140.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $216.00K derived: sum of 2 quarters · filed 2026-03-02 | $120.00K 10-K · filed 2026-03-02 | |
| 2024-09-30 | $76.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$20.00K 10-Q · filed 2024-11-14 | ||
| 2024-06-30 | -$96.00K 10-Q · filed 2024-08-07 | |||
| 2023-12-31 | $264.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $303.00K derived: sum of 2 quarters · filed 2026-03-02 | $312.00K derived: sum of 3 quarters · filed 2026-03-02 | $332.00K 10-K · filed 2026-03-02 |
| 2023-09-30 | $39.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $48.00K derived: sum of 2 quarters · filed 2023-11-13 | $68.00K 10-Q · filed 2023-11-13 | |
| 2023-06-30 | $9.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $29.00K 10-Q · filed 2023-08-09 | ||
| 2023-03-31 | $20.00K 10-Q · filed 2023-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |